Critical Contrast: Soleno Therapeutics (NASDAQ:SLNO) & GETINGE AB/ADR (NASDAQ:GNGBY)

Soleno Therapeutics (NASDAQ:SLNO) and GETINGE AB/ADR (OTCMKTS:GNGBY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares Soleno Therapeutics and GETINGE AB/ADR’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Soleno Therapeutics $1.45 million 39.89 -$13.34 million ($0.65) -2.80
GETINGE AB/ADR $2.67 billion 1.48 -$111.30 million N/A N/A

Soleno Therapeutics has higher earnings, but lower revenue than GETINGE AB/ADR.

Volatility & Risk

Soleno Therapeutics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, GETINGE AB/ADR has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500.

Dividends

GETINGE AB/ADR pays an annual dividend of $0.07 per share and has a dividend yield of 0.5%. Soleno Therapeutics does not pay a dividend.

Institutional and Insider Ownership

46.0% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of GETINGE AB/ADR shares are owned by institutional investors. 26.6% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Soleno Therapeutics and GETINGE AB/ADR, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soleno Therapeutics 0 0 2 0 3.00
GETINGE AB/ADR 0 0 0 0 N/A

Soleno Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 312.09%. Given Soleno Therapeutics’ higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than GETINGE AB/ADR.

Profitability

This table compares Soleno Therapeutics and GETINGE AB/ADR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soleno Therapeutics N/A -108.01% -60.32%
GETINGE AB/ADR -2.41% 8.50% 3.81%

Summary

Soleno Therapeutics beats GETINGE AB/ADR on 8 of the 13 factors compared between the two stocks.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

GETINGE AB/ADR Company Profile

Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Surgical Workflows, and Life Science segments. It offers practice-oriented monitoring systems and disposables; anesthesia, beating heart surgery, and ceiling devices; washer-disinfectors, consumables, and IT-solutions; connected solutions; consumables products; drain products; endoscope reprocessing; endoscopic vessel harvesting systems; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packaging services; intra-aortic balloon counter pulsation therapies; critical care ventilators; modular room systems; operating lights; operating tables and accessories; operating room (OR) furniture; OR integration systems; patient flow management solutions; patient transport solutions; sealing equipment; sterile supply management and traceability solutions; sterilizers; surgical assist systems; surgical perfusion components; loading and distribution trolleys; trays and baskets; and after sales consulting services. The company also provides automated bedding handling equipment, closure processing systems, washers, and isolation and sterile transfer products; professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in Europe, the Middle East, Africa, the Americas, Asia, and Pacific. The company has a strategic partnership with Verb Surgical Inc. to develop digital surgery solutions. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.